Sorafenib exerts its antitumor effect through the inhibition of several targets involved in HCC angiogenesis and progression, including vascular endothelial growth factor receptors (VEGFRs) 1-3, platelet-derived growth factor receptor beta (PDGFR-β), mast/stem cell growth factor receptor (c-KIT) and rearranged during transfection (RET), as well as several rapidly accelerated fibrosarcoma (Raf) kinases [4,7,69]. Here, PDGFRB is linked to hepatocellular carcinoma.